Clinically, therapeutic approaches aimed at augmenting cholinergic function with cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) have been used to treat mild cognitive impairment (MCI), Alzheimer disease, and related dementias [22], underscoring the significance of neuromodulators such as acetylcholine in preserving the chemical integrity of the brain [6,23-25]. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.